Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lakefront Biotherapeutics NVLKFT -1.85%62 EV-to-OCF is 2.64 as of Aug. 30, 2026, which is 2% above its 10-year median of 2.59. GuruFocus rates LKFT with a GF Score™ of 62/100 and a GF Value™ of $113.58 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, Lakefront Biotherapeutics NV ranks worse than 79.55% on this metric.
The historical rank and industry rank for Lakefront Biotherapeutics NV's EV-to-OCF or its related term are showing as below:
LKFT'
s EV-to-OCF Range Over the Past 10 Years
Min: -85.26 Med: 2.59 Max: 11.82
Current: 2.62
During the past 13 years, the highest EV-to-OCF of Lakefront Biotherapeutics NV was 11.82. The lowest was -85.26. And the median was 2.59.
LKFT's EV-to-OCF is ranked worse than 79.55% of 1408
companies
in the Biotechnology industry
Industry Median: -3.72
vs LKFT: 2.62
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lakefront Biotherapeutics NV's PE Ratio (TTM) for today is calculated as:
Lakefront Biotherapeutics NV's share price for today is $28.88.
Lakefront Biotherapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.585.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lakefront Biotherapeutics NV EV-to-OCF Related Terms
Lakefront Biotherapeutics NV EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's EV-to-OCF falls into.
Lakefront Biotherapeutics NV's current Enterprise Value is $-696 Mil.
Lakefront Biotherapeutics NV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-264 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (LKFT) has a EV-to-OCF of 2.64 as of Aug. 30, 2026. This is near median its historical median of 2.59. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #1120 out of 1408 companies in the Biotechnology industry, placing it in the top 79.5%.
Is Lakefront Biotherapeutics NV's EV-to-OCF too high?
Lakefront Biotherapeutics NV's current EV-to-OCF of 2.64 is near median its 10-year median of 2.59. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #1120 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #1120 out of 1408 companies for EV-to-OCF. This places Lakefront Biotherapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Lakefront Biotherapeutics NV's current EV-to-OCF is 2.64, which is near median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is $113.58, compared to a current price of $28.88 — trading 74.6% below its estimated fair value. The current EV-to-OCF is 2.64, which is near median its 10-year median of 2.59. Lakefront Biotherapeutics NV's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (LKFT), the current EV-to-OCF is 2.64 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $28.88 is trading 74.6% below its estimated GF Value™ of $113.58.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for LKFT:
EV-to-OCF: 2.64 (near median its 10-year median of 2.59)
GF Value™: $113.58 vs. price of $28.88 (74.6% below fair value)
No single metric tells the full story. See the LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
62GF Score
Get the complete analysis for LKFT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LKFT has been successfully added to your 
